A new breakthrough could change how high cholesterol is treated, offering a powerful alternative to traditional drugs. Researchers have developed tiny DNA-based molecules that shut down PCSK9—a key ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials RAHWAY, N.J.--(BUSINESS WIRE)- ...

In 1985, the Nobel Prize in Physiology or Medicine was awarded to Michael Brown and Joseph Goldstein for identifying the receptor that clears LDL particles from the bloodstream. High blood levels of ...

National Institute of Health (NIH) scientists have made a significant breakthrough in understanding how "bad" cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body.

An investigational drug, currently known as AZD0780, lowers low-density-lipoprotein cholesterol (LDL-C) to target levels in most patients whose cholesterol is still over target despite statin therapy, ...

Cholesterol lowering with a strategy using the short interfering RNA agent, inclisiran, earlier in the treatment pathway led to significantly better long-term low-density lipoprotein (LDL) reduction ...

Researchers used tiny DNA-based molecules to cut levels of LDL (bad) cholesterol by nearly 50% in animal models. This was ...

Berberine, a plant-derived compound long used in traditional medicine, is gaining attention for its ability to modestly lower LDL cholesterol and triglycerides while supporting blood sugar control.

A concise, high-yield guide to cholesterol-lowering therapies—statins, Zetia, PCSK9 inhibitors, bempedoic acid, berberine, and key dietary tweaks—plus insights on benefits, risks, and mechanisms.